Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Treatment options in HBV.

Antonio Craxì1, Giorgio Antonucci, Calogero Cammà

  • 1Clinica Medica I, Cattedra di Gastroenterologia, University of Palermo, Piazza delle Cliniche 2, 90127 Palermo, Italy. craxanto@unipa.it

Journal of Hepatology
|December 17, 2005
PubMed
Summary

Standard interferon-alpha (IFN) therapy effectively clears HBeAg, HBV-DNA, and HBsAg in chronic hepatitis B patients. Long-term benefits of lamivudine and adefovir for hepatitis B virus (HBV) require further study.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Management of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): Facts and Hopes.

Journal of clinical and experimental hepatology·2026
Same author

Comparison of diagnostic performances of HDV-RNA quantification assays used in clinical practice: Results from a national quality control multicenter study.

Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology·2025
Same author

Point-of-Care Testing and Treatment of Hepatitis C Virus in Prisons: The SINTESI Project in Sicily.

Mayo Clinic proceedings. Innovations, quality & outcomes·2025
Same author

Quality Measures to Enhance the Management and Treatment of Primary Biliary Cholangitis: A Delphi Consensus Study.

Liver international : official journal of the International Association for the Study of the Liver·2025
Same author

What is the benefit of prophylaxis to prevent HBV reactivation in HBsAg-negative anti-HBc-positive patients? Meta-analysis and decision curve analysis.

Liver international : official journal of the International Association for the Study of the Liver·2024
Same author

A holistic evaluation of patients with chronic Hepatitis D virus (HDV) infection enrolled in the Italian PITER-B and delta cohort.

International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases·2024

Area of Science:

  • Hepatology
  • Virology
  • Pharmacology

Background:

  • Chronic hepatitis B (CHB) poses a significant global health challenge.
  • Interferon-alpha (IFN), lamivudine, and adefovir are established treatments for CHB.
  • Optimal treatment strategies and long-term outcomes require ongoing evaluation.

Purpose of the Study:

  • To evaluate the efficacy of standard interferon-alpha (IFN) therapy for HBeAg-positive and HBeAg-negative chronic hepatitis B.
  • To assess the role of lamivudine and adefovir in managing CHB, particularly in specific patient populations.
  • To review the current evidence on treatment outcomes and identify areas for future research.

Main Methods:

  • Systematic review of available evidence on IFN, lamivudine, and adefovir for CHB.
  • Analysis of treatment efficacy based on virological markers (HBeAg, HBV-DNA, HBsAg) and clinical outcomes.
  • Assessment of treatment resistance and long-term sustained response.

Main Results:

  • Standard IFN significantly improves HBeAg clearance (NNT=4), HBV-DNA loss (NNT=4), and HBsAg clearance (NNT=18) in HBeAg-positive CHB.
  • IFN is recommended for HBeAg-positive patients with normal/elevated ALT only if histological evidence of disease progression exists.
  • Sustained virological response after IFN in HBeAg-negative CHB is <20%; long-term benefits require further study.
  • Lamivudine effectively reduces HBV replication in immunosuppressed patients and those with advanced liver disease.
  • Adefovir is preferred over lamivudine as a first-line treatment due to lower resistance rates, excluding cost considerations.
  • Long-term benefits and the role of combination therapies with lamivudine and adefovir are under investigation.

Conclusions:

  • Standard IFN is effective for HBeAg-positive CHB, with specific indications for HBeAg-negative CHB.
  • Lamivudine and adefovir offer treatment options for specific CHB patient groups, with adefovir showing a lower resistance profile.
  • Further research is needed to establish the long-term efficacy of antiviral therapies and combination strategies in CHB management.

Related Experiment Videos